Overview
Sight Sciences Q3 2025 revenue beats analyst expectations despite a 1% yr/yr decline
Company raises full-year 2025 revenue guidance to $76-78 mln, up from $72-76 mln
Operating expenses decreased 11% yr/yr in Q3 2025, including $2.8 mln in restructuring costs
Outlook
Sight Sciences raises 2025 revenue guidance to $76.0 mln to $78.0 mln
Company reduces 2025 adjusted operating expenses guidance to $90 mln to $92 mln
Company expects tariffs to increase Surgical Glaucoma costs by $1.0 mln to $1.5 mln in 2025
Result Drivers
SURGICAL GLAUCOMA GROWTH - Revenue growth driven by increased ordering accounts and higher average selling prices, despite coverage restrictions
DRY EYE REVENUE DECLINE - Significant decline due to focus on achieving reimbursed market access for TearCare procedures
OPERATING EXPENSE REDUCTION - Operating expenses decreased due to restructuring and cost management efforts
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $19.90 mln | $17.70 mln (6 Analysts) |
Q3 Net Income | -$8.20 mln | ||
Q3 Gross Margin | 86.00% | ||
Q3 Gross Profit | $17.20 mln | ||
Q3 Operating Expenses | $25.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Sight Sciences Inc is $4.00, about 25.8% below its November 5 closing price of $5.03
Press Release: ID:nGNX6xypCY
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)